WO2024150170 - PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA
National phase entry:
Publication Number
WO/2024/150170
Publication Date
18.07.2024
International Application No.
PCT/IB2024/050296
International Filing Date
11.01.2024
Title **
[English]
PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA
[French]
PIROMÉLATINE POUR LE TRAITEMENT DE PARASOMNIES ASSOCIÉES À UNE PERTE DE L'ATONIE PROPRE AU SOMMEIL PARADOXAL
Applicants **
NEURIM PHARMACEUTICALS (1991) LTD.
Inventors
FURMAN, Ran
ZISAPEL, Nava
Priority Data
63/479,781
13.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2609 | |
| EPO | Filing, Examination, Granting | 18405 | |
| Japan | Filing, Examination, Granting | 2855 | |
| South Korea | Filing, Examination, Granting | 3521 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
36,130
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods of treating a subject having parasomnias related to Rapid Eye Movement (REM) sleep and attenuating disease progression into synucleinopathies and Parkinson's disease by administering a formulation comprising an effective amount of piromelatine to the subject. Methods of treating a subject having parasomnias related to Rapid Eye Movement (REM) sleep and attenuating disease progression of parasomnias into chronic post-traumatic stress disorder (PTSD) by administering a formulation comprising of an effective amount of piromelatine to a subject.[French]
L'invention concerne des méthodes de traitement d'un sujet atteint de parasomnies liées au sommeil paradoxal (à mouvement oculaire rapide (MOR)) et d'atténuation de la progression d'une maladie dans des synucléinopathies et la maladie de Parkinson par administration au sujet d'une formulation comprenant une quantité efficace de piromélatine. L'invention concerne également des méthodes de traitement d'un sujet atteint de parasomnies liées au sommeil paradoxal (à mouvement oculaire rapide (MOR)) et d'atténuation de la progression de la maladie de parasomnies en un trouble de stress post-traumatique (TSPT) chronique par l'administration d'une formulation comprenant une quantité efficace de piromélatine à un sujet.